GlobeImmune Statistics

Total Valuation

GlobeImmune has a market cap or net worth of 575.

Market Cap	575
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

GlobeImmune has 5.75 million shares outstanding.

Current Share Class	5.75M
Shares Outstanding	5.75M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.00
PB Ratio	0.00
P/TBV Ratio	0.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.28

Current Ratio	2.28
Quick Ratio	2.10
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -66.24% and return on invested capital (ROIC) is -41.40%.

Return on Equity (ROE)	-66.24%
Return on Assets (ROA)	-10.25%
Return on Invested Capital (ROIC)	-41.40%
Return on Capital Employed (ROCE)	-36.77%
Revenue Per Employee	2.07M
Profits Per Employee	-689,528
Employee Count	3
Asset Turnover	0.49
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9,900.00% in the last 52 weeks. The beta is -291.29, so GlobeImmune's price volatility has been lower than the market average.

Beta (5Y)	-291.29
52-Week Price Change	+9,900.00%
50-Day Moving Average	0.00
200-Day Moving Average	0.54
Relative Strength Index (RSI)	42.65
Average Volume (20 Days)	3,416

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.83

Income Statement

In the last 12 months, GlobeImmune had revenue of 6.21 million and -2.07 million in losses. Loss per share was -0.36.

Revenue	6.21M
Gross Profit	4.13M
Operating Income	-2.07M
Pretax Income	-2.07M
Net Income	-2.07M
EBITDA	-1.94M
EBIT	-2.07M
Loss Per Share	-0.36

Full Income Statement

Balance Sheet

The company has 8.69 million in cash and n/a in debt, giving a net cash position of 8.69 million or 1.51 per share.

Cash & Cash Equivalents	8.69M
Total Debt	n/a
Net Cash	8.69M
Net Cash Per Share	1.51
Equity (Book Value)	2.15M
Book Value Per Share	0.37
Working Capital	5.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.90 million and capital expenditures -11,805, giving a free cash flow of -5.92 million.

Operating Cash Flow	-5.90M
Capital Expenditures	-11,805
Free Cash Flow	-5.92M
FCF Per Share	-1.03

Full Cash Flow Statement

Margins

Gross margin is 66.52%, with operating and profit margins of -33.30% and -33.30%.

Gross Margin	66.52%
Operating Margin	-33.30%
Pretax Margin	-33.30%
Profit Margin	-33.30%
EBITDA Margin	-31.25%
EBIT Margin	-33.30%
FCF Margin	n/a

Dividends & Yields

GlobeImmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-32.85%
Shareholder Yield	-32.85%
Earnings Yield	-359,753.91%
FCF Yield	-1,028,991.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GlobeImmune has an Altman Z-Score of -30.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-30.24
Piotroski F-Score	2